Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Insulin prices

- PMLiVE

Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine

Sanofi reception

Sanofi/Regeneron’s Sarilumab cleared by FDA on second attempt

IL-6 inhibitor to treat adult RA patients

- PMLiVE

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes

- PMLiVE

Eli Lilly appoints senior VP for corporate affairs and communications

Leigh Ann Pusey joins from the American Insurance Association

Sanofi targets patient literacy in clinical trials drive

Unveils new online resources for those in the US

Sanofi reception

Sanofi agrees €250m diabetes deal with AI firm Exscientia

The French pharma giant will pay royalties and contribute research funding

Eli Lilly HQ

Surging Trulicity takes sting out of Lilly’s arthritis setback

First quarter sales of the diabetes treatment were up by 160%, exceeding analysts predictions

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

Amgen sues Sanofi and Regeneron over eczema drug

Alleges patent infringement and seeks financial reparations

Eli Lilly HQ

FDA turns down Lilly and Incyte JAK inhibitor after delay

Analysts suggest safety issues in high doses

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

- PMLiVE

Sanofi appoints Bill Sibold to lead its Genzyme business

He will succeed David Meeker, who is leaving in the firm in June

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links